{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:53:32Z","timestamp":1780437212555,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13000-016-0547-6","type":"journal-article","created":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T08:41:44Z","timestamp":1475829704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy"],"prefix":"10.1186","volume":"11","author":[{"given":"Tanja","family":"Kersnik Levart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Du\u0161an","family":"Ferluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"Vizjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerica","family":"Mraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Kojc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,7]]},"reference":[{"key":"547_CR1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semnephrol.2011.06.005","volume":"31","author":"S Sethi","year":"2011","unstructured":"Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol. 2011;31:341\u20138.","journal-title":"Semin Nephrol."},{"key":"547_CR2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMra1108178","volume":"366","author":"S Sethi","year":"2012","unstructured":"Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis \u2013 a new look at an old entity. N Engl J Med. 2012;366:1119\u201331.","journal-title":"N Engl J Med."},{"key":"547_CR3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/ki.2011.399","volume":"5","author":"S Sethi","year":"2012","unstructured":"Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012;5:434\u201341.","journal-title":"Kidney Int."},{"key":"547_CR4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering MC, D\u2019Agati VD, Nester CM, Smith JR, Haas M, Appel BG, et al. C3 glomerulopathy: consensus report. Kidney Int. 2013;84:1079\u201389.","journal-title":"Kidney Int."},{"key":"547_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MNH.0b013e32835ff9cb","volume":"22","author":"HT Cook","year":"2013","unstructured":"Cook HT. Complement and kidney disease. Curr Opin Nephrol Hypertens. 2013;22:295\u2013301.","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"547_CR6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","volume":"9","author":"NR Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas NR, O\u2019Shaughnessy MM, O\u2019Regan JA, Traynor C, Flanagan M, Wong L, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol. 2014;9:46\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"547_CR7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","volume":"66","author":"M Noris","year":"2015","unstructured":"Noris M, Remuzzi G. Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis. 2015;66:359\u201375.","journal-title":"Am J Kidney Dis"},{"key":"547_CR8","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ki.2013.340","volume":"85","author":"J Hou","year":"2014","unstructured":"Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2014;85:450\u20136.","journal-title":"Kidney Int"},{"key":"547_CR9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MNH.0b013e328345848b","volume":"20","author":"M Pickering","year":"2011","unstructured":"Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens. 2011;20:271\u20137.","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"547_CR10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.2012.212","volume":"82","author":"S Sethi","year":"2012","unstructured":"Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012;82:465\u201373.","journal-title":"Kidney Int."},{"key":"547_CR11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1055\/s-0034-1376334","volume":"40","author":"X Xiao","year":"2014","unstructured":"Xiao X, Pickering MC, Smith RJH. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Semin Thromb Hemost. 2014;40:465\u201371.","journal-title":"Semin Thromb Hemost."},{"key":"547_CR12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/jmg.2005.038315","volume":"43","author":"MA Abrera-Abeleda","year":"2006","unstructured":"Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet. 2006;43:582\u20139.","journal-title":"J Med Genet."},{"key":"547_CR13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/jmg.40.9.676","volume":"40","author":"HP Neumann","year":"2003","unstructured":"Neumann HP, Salzmann M, Bohnert-Iwan B, Mannuelian T, Skerka C, Lenk D, et al. Haemolytic uraemic syndrome in mutations of the factor H gene: a registry based study of German speaking countries. J Med Genet. 2003;40:676\u201381.","journal-title":"J Med Genet."},{"key":"547_CR14","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1093\/hmg\/ddg363","volume":"12","author":"J Caprioli","year":"2003","unstructured":"Caprioli J, Castekketti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257\u00a0T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet. 2003;12:3385\u201395.","journal-title":"Hum Mol Genet."},{"key":"547_CR15","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJMc1106619","volume":"366","author":"S Radhakrishnan","year":"2012","unstructured":"Radhakrishnan S, Lunn A, Kirschfink M, Thormer P, Hebert D, Langlois V, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med. 2012;366:1165\u20136.","journal-title":"N Engl J Med."},{"key":"547_CR16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","volume":"7","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher CE, Herlitz L, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012;7:748\u201356.","journal-title":"Clin J Am Soc Nephrol."},{"key":"547_CR17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT, Loirat C. Fr\u00e9meaux-Bacchi on behalf of the French Study Group for aHUS\/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Rev Nephrol. 2012;8:643\u201357.","journal-title":"Nature Rev Nephrol"},{"key":"547_CR18","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1681\/ASN.2011121186","volume":"23","author":"LC Herlitz","year":"2012","unstructured":"Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol. 2012;23:1229\u201337.","journal-title":"J Am Soc Nephrol."},{"key":"547_CR19","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1007\/s00467-013-2503-y","volume":"28","author":"S Gurkan","year":"2013","unstructured":"Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol. 2013;28:1975\u201381.","journal-title":"Pediatr Nephrol."},{"key":"547_CR20","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00467-013-2565-x","volume":"28","author":"E Kerns","year":"2013","unstructured":"Kerns E, Rozansky D, Troxell ML. Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy. Pediatr Nephrol. 2013;28:2227\u201331.","journal-title":"Pediatr Nephrol."},{"key":"547_CR21","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-0034-1375299","volume":"40","author":"M Vivarelli","year":"2014","unstructured":"Vivarelli M, Emma F. Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost. 2014;40:472\u20137.","journal-title":"Semin Thromb Hemost."},{"key":"547_CR22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000368592","volume":"3-4","author":"AS Bomback","year":"2014","unstructured":"Bomback AS. Eculizumab in the treatment of membranoproliferative glomerulonephritis. Nephron Clin Pract. 2014;3-4:270\u20136.","journal-title":"Nephron Clin Pract"},{"key":"547_CR23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00467-015-3061-2","volume":"6","author":"A Payatte","year":"2015","unstructured":"Payatte A, Patey N, Dragon-Durey MA, Fremeaux-Bacchi V, Le Deist F, Lapeyraque AL. A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol. 2015;6:1033\u20137.","journal-title":"Pediatr Nephrol."},{"key":"547_CR24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","volume":"3","author":"M Quintrec Le","year":"2015","unstructured":"Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis. 2015;3:484\u20139.","journal-title":"Am J Kidney Dis."},{"key":"547_CR25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ckj\/sfv044","volume":"4","author":"M Inman","year":"2015","unstructured":"Inman M, Prater G, Fatima H, Wallace E. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J. 2015;4:445\u20138.","journal-title":"Clin Kidney J."},{"key":"547_CR26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"4","author":"A Servais","year":"2012","unstructured":"Servais A, Noel LH, Roumenina LT, Le Quintec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;4:454\u201364.","journal-title":"Kidney Int."},{"key":"547_CR27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ki.2012.384","volume":"83","author":"S Sethi","year":"2013","unstructured":"Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, et al. Atypical post-infectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int. 2013;83:293\u20139.","journal-title":"Kidney Int."},{"key":"547_CR28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1053\/j.ajkd.2012.04.032","volume":"60","author":"G Sandhu","year":"2012","unstructured":"Sandhu G, Bansal A, Ranade A, Jones J, Cortel S, Markowitz G. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am J Kidney Dis. 2012;60:1039\u201343.","journal-title":"Am J Kidney Dis."},{"key":"547_CR29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MOP.0b013e32835df4a3","volume":"25","author":"C Nester","year":"2013","unstructured":"Nester C, Brophy PD. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Curr Opin Pediatr. 2013;25:225\u201331.","journal-title":"Curr Opin Pediatr."},{"key":"547_CR30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ckj\/sfv065","volume":"4","author":"L Rodriguez-Osorio","year":"2015","unstructured":"Rodriguez-Osorio L, Ortiz A. Timing of eculizumab therapy fpr C3 glomerulonephritis. Clin Kidney J. 2015;4:449\u201352.","journal-title":"Clin Kidney J."},{"key":"547_CR31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21757","volume":"85","author":"P Hillmen","year":"2010","unstructured":"Hillmen P, Elebute M, Kelly R, Urbano-Ispizua A, Hill A, Rother RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85:553\u20139.","journal-title":"Am J Hematol."}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-016-0547-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T20:36:00Z","timestamp":1498336560000},"score":1,"resource":{"primary":{"URL":"http:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-016-0547-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["547"],"URL":"https:\/\/doi.org\/10.1186\/s13000-016-0547-6","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727214540.793528921","asserted-by":"object"}]},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,7]]},"article-number":"94"}}